Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer

The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.

NCT Number	NCT07528430
Lead Sponsor	University of Maryland, Baltimore Collaborators: EPOCH Epigenetics, Inc
Conditions	Pancreatic Cancer, Advanced or Metastatic
Enrollment	450 participants
Start Date	2026-09-01
Primary Completion	2032-10 (estimated)
Study Completion	2032-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-29